ArticleHaematologica2015
MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition.
Article in Haematologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 55 citations in OpenAlex.
- Trial
- Therapeutic targeting of chromatin alterations in leukemia and solid tumors.International journal of cancer · 2026Review
- Dysregulation of HOXA genes in acute myeloid leukemia and targeted therapy.NPJ precision oncology · 2025Review
- Chromatin Regulatory Targets for Anticancer Therapeutics.Chemical reviews · 2025Review
- Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research.International journal of molecular sciences · 2023Review
- Translating recent advances in the pathogenesis of acute myeloid leukemia to the clinic.Genes & development · 2022Review
- Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia.International journal of molecular sciences · 2022Review
- The Role of DOT1L in Normal and Malignant Hematopoiesis.Frontiers in cell and developmental biology · 2022Review
- Non-canonical H3K79me2-dependent pathways promote the survival of MLL-rearranged leukemia.eLife · 2021Article
- Article
- Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies.Journal of Korean medical science · 2021Review
- DOT1L inhibitors block abnormal self-renewal induced by cohesin loss.Scientific reports · 2021Article
- Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.Blood · 2020Article
- Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective ofCancers · 2020Article
- Specific patterns of H3K79 methylation influence genetic interaction of oncogenes in AML.Blood advances · 2020Article
- DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway.Oncotarget · 2020Article
- SplintQuant: a method for accurately quantifying circular RNA transcript abundance without reverse transcription bias.RNA (New York, N.Y.) · 2019Article
- Direct and Indirect Targeting of HOXA9 Transcription Factor in Acute Myeloid Leukemia.Cancers · 2019Review
- Therapeutic targeting potential of chromatin-associated proteins in MLL-rearranged acute leukemia.Cellular oncology (Dordrecht, Netherlands) · 2019Review
- Targeted Therapies for Pediatric AML: Gaps and Perspective.Frontiers in pediatrics · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.